Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cocrystal Pharma Inc (COCP)

Cocrystal Pharma Inc (COCP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cocrystal Pharma Inc 19805 N. CREEK PARKWAY BOTHELL WA 98011 USA

P: 786-459-1831

Description:

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HepC. Phase 1b studies in HepC infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 6 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 48% of the Company.

Key Statistics

Overview:

Market Capitalization, $K 69,690
Shares Outstanding, K 97,469
Annual Sales, $ 2,010 K
Annual Net Income, $ -9,650 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -3,940 K
60-Month Beta 1.13
% of Insider Shareholders 8.30%
% of Institutional Shareholders 24.16%
Float, K 89,379
% Float 91.70%

Growth:

1-Year Return -56.40%
3-Year Return -80.57%
5-Year Return -94.41%
5-Year Revenue Growth 2,412.50%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 11/15/21
Earnings Per Share ttm -0.13
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 20.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-30 on 01/24/18

COCP Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -17.75%
Return-on-Assets % -17.25%
Profit Margin % -480.10
Net Margin % N/A
Debt/Equity 0.00
Price/Sales 36.93
Price/Cash Flow N/A
Price/Book 0.92
Book Value/Share 0.83
Interest Coverage -964.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar